A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.
Mita M, LoRusso P, McArthur G, Kim E, Bray G, Hock N, Laille E, Aronchik I, Filvaroff E, Wu X, Bendell J. A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors. Journal Of Clinical Oncology 2017, 35: 2577-2577. DOI: 10.1200/jco.2017.35.15_suppl.2577.Peer-Reviewed Original ResearchBRAF-mutant tumorsObjective responsePK parametersMutant tumorsDose reduction/interruptionGrade 3 transaminase elevationPeripheral blood mononuclear cellsPhase Ia studyReduction/interruptionBlood mononuclear cellsExtracellular signal-regulated kinase (ERK) inhibitorSignal-regulated kinase inhibitorPotent anti-proliferative activityRECIST 1.1Transaminase elevationNeurologic toxicityNineteen patientsMononuclear cellsMultiple dosesRAS mutant tumorsHuman studiesPatientsPK profilesAnti-proliferative activityGrade 1